Access Financial Services Inc. reduced its stake in Johnson & Johnson (NYSE:JNJ – Get Rating) by 11.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,118 shares of the company’s stock after selling 1,318 shares during the quarter. Johnson & Johnson comprises approximately 1.1% of Access Financial Services Inc.’s portfolio, making the stock its 14th biggest holding. Access Financial Services Inc.’s holdings in Johnson & Johnson were worth $1,787,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Veracity Capital LLC increased its holdings in Johnson & Johnson by 1.2% in the 4th quarter. Veracity Capital LLC now owns 5,027 shares of the company’s stock worth $888,000 after acquiring an additional 59 shares in the last quarter. Sandy Cove Advisors LLC increased its holdings in Johnson & Johnson by 1.6% in the 3rd quarter. Sandy Cove Advisors LLC now owns 3,703 shares of the company’s stock worth $605,000 after acquiring an additional 60 shares in the last quarter. Paces Ferry Wealth Advisors LLC increased its holdings in Johnson & Johnson by 0.7% in the 3rd quarter. Paces Ferry Wealth Advisors LLC now owns 8,724 shares of the company’s stock worth $1,425,000 after acquiring an additional 62 shares in the last quarter. Mason & Associates Inc increased its holdings in Johnson & Johnson by 4.9% in the 3rd quarter. Mason & Associates Inc now owns 1,317 shares of the company’s stock worth $215,000 after acquiring an additional 62 shares in the last quarter. Finally, Magnolia Capital Advisors LLC increased its holdings in Johnson & Johnson by 0.7% in the 3rd quarter. Magnolia Capital Advisors LLC now owns 8,883 shares of the company’s stock worth $1,451,000 after acquiring an additional 62 shares in the last quarter. 67.94% of the stock is owned by hedge funds and other institutional investors.
Insider Activity
In other news, insider James D. Swanson sold 1,062 shares of the firm’s stock in a transaction on Monday, March 6th. The stock was sold at an average price of $154.66, for a total transaction of $164,248.92. Following the transaction, the insider now owns 9,215 shares in the company, valued at $1,425,191.90. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.35% of the company’s stock.
Johnson & Johnson Stock Up 1.0 %
Johnson & Johnson (NYSE:JNJ – Get Rating) last released its earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share for the quarter, topping the consensus estimate of $2.22 by $0.13. Johnson & Johnson had a return on equity of 35.76% and a net margin of 18.90%. The business had revenue of $23.71 billion during the quarter, compared to the consensus estimate of $23.90 billion. During the same period last year, the company earned $2.13 earnings per share. The business’s revenue for the quarter was down 4.4% compared to the same quarter last year. On average, sell-side analysts expect that Johnson & Johnson will post 10.5 EPS for the current year.
Johnson & Johnson Announces Dividend
The company also recently declared a quarterly dividend, which was paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st were paid a dividend of $1.13 per share. The ex-dividend date of this dividend was Friday, February 17th. This represents a $4.52 annualized dividend and a dividend yield of 2.92%. Johnson & Johnson’s dividend payout ratio is currently 67.06%.
Wall Street Analysts Forecast Growth
A number of brokerages have issued reports on JNJ. UBS Group began coverage on shares of Johnson & Johnson in a report on Tuesday. They set a “neutral” rating and a $164.00 price objective for the company. StockNews.com initiated coverage on shares of Johnson & Johnson in a report on Thursday, March 16th. They issued a “strong-buy” rating for the company. Piper Sandler cut their target price on shares of Johnson & Johnson from $55.00 to $52.00 in a report on Monday, February 6th. Citigroup raised their target price on shares of Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a report on Monday, December 12th. Finally, Morgan Stanley raised their target price on shares of Johnson & Johnson from $176.00 to $180.00 and gave the company an “equal weight” rating in a report on Wednesday, January 25th. Eight investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and an average target price of $173.67.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Featured Stories
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- What is a Gold IRA, and is it a Viable Investment?
- Is Braze, Inc Ready To Rocket Higher?
- Mullen Automotive Makes Deliveries; Short-Squeeze Possible
- Can Frontline Maintain This Momentum?
- Walmart Shares Jump on Evercore Analyst Upgrade
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
